false 0001175151 0001175151 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

Amendment No. 1 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

Cytosorbents Corporation

(Exact name of registrant as specified in its charter) 

 

Delaware   001-36792   98-0373793
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

305 College Road East

Princeton, New Jersey

  08540
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code (973) 329-8885

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value CTSO The NASDAQ Stock Market LLC
(Nasdaq Capital Market)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Explanatory Note

 

This Amendment No. 1 on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2026 (the “Original 8-K”) by CytoSorbents Corporation (the “Company”). The Company is filing this Amendment solely to correct certain financial information contained in the press release issued by the Company on November 12, 2026, announcing, among other things, its financial results for the quarter ended September 30, 2026 (the “Original Press Release”), which was furnished as Exhibit 99.1 to the Original 8-K.

 

The Company is furnishing a revised press release, dated November 19, 2026 (the “Revised Press Release”), to correct immaterial errors in the foreign currency transaction loss previously recognized and related amounts, certain balance sheet and stockholders’ equity (deficit) amounts, selling, general and administrative expenses and restructuring expenses for the nine months ended September 30, 2026, and certain revenue growth and sales mix percentages, to conform to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

 

The Revised Press Release is furnished with this Amendment as Exhibit 99.1 and supersedes and replaces the Original Press Release furnished as Exhibit 99.1 to the Original 8-K.

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 12, 2026, the Company issued the Original Press Release announcing its financial results for the quarter ended September 30, 2026. As described in the Explanatory Note above, the Company is furnishing the Revised Press Release as Exhibit 99.1 to this Amendment.*

 

Item 7.01. Regulation FD Disclosure.

 

For the benefit of its investors, the Company is furnishing an updated investor presentation in connection with its earnings conference call. A copy of the updated investor presentation is being furnished as Exhibit 99.2.*

 

Item 9.01 Exhibits

 

(d) Exhibits

 

Exhibit
No.
Description
99.1 Revised Press Release of the Company, dated November 19, 2026
99.2 Revised Investor Presentation
104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

* The information in Items 2.02 and 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 19, 2026 CYTOSORBENTS CORPORATION
     
  By: /s/ Dr. Phillip P. Chan
  Name: Dr. Phillip P. Chan
  Title: Chief Executive Officer